Lilly promises to make weight-loss pill in United States in reshoring push
By making the expected blockbuster pill in the U.S., Lilly may be able to avoid the impact of Trump’s sweeping tariffs, including possible levies on pharmaceutical products.
Pharmaceutical
Articles
Lilly stock soars after weight-loss pill’s trial results rival Ozempic’s shot
Trial data data showed Lilly’s experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to injections.
Trump orders new efforts to lower drug prices
Trump’s order contains proposals to further lower the cost of insulin, importing more low-cost drugs and streamlining the federal approval process for some drugs.
Irish pharma exports to United States surge amid tariff threat
It was the second straight sizable increase, suggesting that U.S. drug makers with Irish manufacturing hubs like Indianapolis-based Eli Lilly and Co. could be stockpiling products ahead of any tariffs on the sector.
Pfizer ends development of potential pill obesity treatment
Pfizer had been hoping the once-daily pill treatment would give it an edge over leading weight-loss treatments like Zepbound from Eli Lilly and Co. and Novo Nordisk’s Wegovy, which are injectable.
FDA reverses course on telework after layoffs, resignations threaten basic operations
Weeks after ordering all Food and Drug Administration employees back into the office, the agency is allowing some of its most prized staffers to work remotely.
Lilly sues Indianapolis clinic for selling split doses of popular weight-loss drugs
The drugmaker accuses Premier Weight Loss of risking patients’ health by selling altered, unsterile versions of its blockbuster drugs Mounjaro and Zepbound.
Trump administration nixes plan to cover anti-obesity drugs through Medicare
President Trump’s predecessor, Joe Biden, proposed a rule in late November after Trump won re-election that would have extended coverage of drugs like Zepbound and Wegovy.
Johnson & Johnson plans $55B in United States investments
Aside from building four new plants, Johnson & Johnson said that it will expand several existing sites.
Purdue Pharma submits opioid lawsuit settlement plan, including up to $7B from Sacklers
Members of the Sackler family who own the OxyContin maker Purdue Pharma would hand over the company in the latest plan to settle thousands of lawsuits.
Zepbound raises profile of Lilly’s direct-to-consumer sales initiative
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to connect directly with consumers on the platform since.
Novo Nordisk cuts Wegovy prices, following similar move for Zepbound by Eli Lilly
Novo Nordisk’s new offering follows a direct-to-consumer model that Eli Lilly launched last year.
Study co-authored by IU researcher finds generic drugs made in India have more severe adverse events
The results showed that the number of severe adverse events for patients was 54.3% higher than that of drugs made in emerging economies.
Patients struggle with lack of consistent coverage for popular weight-loss drugs
Supplies of high-demand obesity treatments are improving, but that doesn’t mean they’re easier to get.
Lebanon planning board OKs design for Lilly Medicine Foundry at LEAP District
The foundry will give the pharmaceutical maker the ability to research new ways of producing medicines.
Trump casts psychiatric and weight-loss drugs as threats to children
President Donald Trump has instructed his administration to scrutinize the “threat” to children posed by antidepressants, stimulants and other common psychiatric drugs.
IBJ Podcast: The risks tariffs pose to Indiana’s manufacturing-heavy economy
President Trump wasted little time turning to economic policy once his second term began, imposing or threatening to impose a barrage of tariffs on many of Indiana’s trading partners.
Could obesity drugs help with alcohol cravings? New study suggests potential.
The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not just for food, but also for tobacco and alcohol.
FDA approves non-opioid painkiller Journavx
The painkiller is the first novel pain drug to win government authorization in more than 20 years.
Purdue Pharma and owners to pay $7.4B in settlement over OxyContin’s toll
The deal represents an increase of more than $1 billion over a previous settlement deal that was rejected last year by the U.S. Supreme Court.